Abilify news from FiercePharma
News
Rumor mill: BMS positioning itself for sale
Speculation that Bristol-Myers Squibb might be a takeover target -- that's old news. Informed speculation based on certain strategic moves BMS has made recently -- worth passing on. Tim Anderson, the... Read more...
Bristol's Abilify gets nod for adolescents
Better late than never, Bristol-Myers Squibb might say. In a move that's sure to incite debate, the FDA says it will allow BMS to market its schizophrenia med Abilify for use in adolescents. The... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets


